Roberto Sorio

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros et al. · The Lancet Oncology · 2014 · 392 citations

Medicine, Gynecology, Oncology +12

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial

Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina et al. · Journal of Clinical Oncology · 2011 · 227 citations · Full text

Medicine, Oncology, Pharmacology +13

A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis

Andrea Vecchione, Barbara Belletti, Francesca Lovat et al. · Proceedings of the National Academy of Sciences · 2013 · 186 citations · Full text

Medicine, Cancer Biology, Oncology +17

Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

Martin R. Stockler, Felix Hilpert, Michael Friedländer et al. · Journal of Clinical Oncology · 2014 · 175 citations · Full text

Medicine, Oncology, Pharmacotherapy +17